医療従事者の為の最新医療ニュースや様々な情報・ツールを提供する医療総合サイト

MARU Inc.: Japan’s First* Beauty Counseling Cafe That Provides Japanese Latest Beauty Information for Foreigners Who Are Visiting Japan!

2019年07月24日 PM01:26
このエントリーをはてなブックマークに追加


 

OSAKA, Japan

Beauty Counseling Cafe providing the latest beauty information in Japan, such as beauty salons, clinics and hospitals, has been established.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190723006034/en/

Beauty Information Japan "MARU" opened in Dotonbori, Osaka Namba Central Area (Photo: Business Wire)

Beauty Information Japan “MARU” opened in Dotonbori, Osaka Namba Central Area (Photo: Business Wire)

For foreigners visiting Japan, certified medical interpreters provide total support such as counseling, reservation, and interpretive attendance. At the same time, we offer beauty products, health foods and other products related to beauty, and also provide samples and testers.

1. If you feel anxious about cosmetics surgery for the first time
2. If you want to improve your skin troubles
3. If you feel anxious about going to the clinic alone
Those who are troubled by the above reasons could feel free to consult in the opening style cafe. It doesn’t matter if you are alone, and you are welcome to come and experience with your friends.

Our professional staff will provide you with the best solution.

Chinese and English are available.

Beauty Information Japan “MARU”
https://b-i-japan.com/en/
Address: 2F, Dongsan Building, 1-3-15 Dotonbori, Chuo-ku, Osaka
Business hours: 11:00 – 20:00
Off day: Sunday

*According to MARU’s investigation

View source version on businesswire.com: https://www.businesswire.com/news/home/20190723006034/en/

CONTACT

MARU Inc.

MIKI AYA

+81-80-9471-0336

ayamiki@maru.co.jp

Related Posts Plugin for WordPress, Blogger...

同じカテゴリーの記事 

  • アスターDMヘルスケア、25万米ドル相当の世界看護賞を発表
  • Prestige BioPharma Enters MOU with Busan City for Establishment of its R&D Centre in Busan, South Korea
  • Celltrion Confirms Neutralising Potency Against Emerging SARS-CoV-2 Variants With Anti-COVID-19 Monoclonal Antibody Treatment regdanvimab (CT-P59)
  • InnoCare Announces Approval of Clinical Trial of TYK2 Inhibitor ICP-332 in China
  • 患者安全运动基金会公布参加首届医疗安全研究员项目五人名单